Mitoquinol, Methylene Blue & Urolithin A: What's the difference?
MitoQ, Methylene blue, and Urolithin A - are they really interchangeable? In this episode, we break down what each of these mitochondria-targeted compounds actually does in the body, why they're not competing solutions, and what the research says about each one individually.
Why mitochondrial dysfunction is considered a hallmark of aging, and why researchers are targeting it directly
How MitoQ is engineered to accumulate inside the mitochondria and reduce oxidative stress at the source
Why Urolithin A is connected to mitophagy — the cell's process for clearing out damaged mitochondria
How methylene blue works differently again, acting as an alternative electron carrier in the electron transport chain
Where MitoQ and mitophagy intersect
Whether you've been hearing these three names thrown around on longevity podcasts or want to understand the actual biology behind each one, this episode will explain what's really going on at the mitochondrial level.
-
Xiao L, Xu X, Zhang F, et al. (2017). The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biology, 11, 297-311.
DOI: https://doi.org/10.1016/j.redox.2016.12.022van der Rijt S, Molenaars M, McIntyre RL, Janssens GE, Houtkooper RH. (2020). Integrating the Hallmarks of Aging Throughout the Tree of Life: A Focus on Mitochondrial Dysfunction. Frontiers in Cell and Developmental Biology, 8, 594416.
DOI: https://doi.org/10.3389/fcell.2020.594416Liu Y, Wang X, Zhao Y, et al. (2021). Immunomodulatory Role of Urolithin A on Metabolic Diseases. Biomedicines, 9(2), 192.
DOI: https://doi.org/10.3390/biomedicines9020192Rossman MJ, Santos-Parker JR, Steward CAC, et al. (2018). Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Hypertension, 71(6), 1056-1063.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.10787Masoumi-Ardakani Y, Najafipour H, Nasri HR, et al. (2022). Moderate Endurance Training and MitoQ Improve Cardiovascular Function, Oxidative Stress, and Inflammation in Hypertensive Individuals: The Role of miR-21 and miR-222. Cell Journal, 24(10), 577-585.
DOI: https://doi.org/10.22074/cellj.2022.8089Liu S, D'Amico D, Shankland E, et al. (2022). Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open, 5(1), e2144279.
DOI: https://doi.org/10.1001/jamanetworkopen.2021.44279Ryu D, Mouchiroud L, Andreux PA, et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine, 22, 879-888. DOI: https://doi.org/10.1038/nm.4132
Smith RAJ, Murphy MP. (2010). Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Annals of the New York Academy of Sciences, 1201, 96-103.
DOI: https://doi.org/10.1111/j.1749-6632.2010.05627.x
Mentioned in this episode
MitoQ, methylene blue, and urolithin A are frequently discussed as tools for supporting mitochondrial health, but they target different aspects of mitochondrial biology. MitoQ is primarily studied as a mitochondria-targeted antioxidant, urolithin A for its role in mitophagy and mitochondrial quality control, and methylene blue for its role as an alternative electron carrier within the mitochondrial respiratory chain.
This episode explores the science behind these distinct mechanisms and why understanding the underlying biology is more important than asking which compound is "best."
-
Tyla (00:16)
Welcome back to the MitoPod, the podcast exploring mitochondrial health and longevity. I'm Tyla, I'm a qualified naturopath, and I support our host Georgia with all things science communication. And today we're tackling a question that seems to be everywhere right now in the longevity and mitochondrial health space, which is Mito Q, Methylene Blue, and Urolithin A.
If you've been listening to longevity podcasts, you've probably seen all three being discussed as tools to support mitochondrial health. And sometimes they're even presented as interchangeable. But that's actually not what's happening biologically, and each one interacts with mitochondria in a completely different way.
So let's get straight into it. So we know that mitochondria are responsible for producing most of the energy our cells need, but they do a lot more than that. They regulate oxidative stress, influence inflammation, they help coordinate cellular signaling, they participate in quality control processes
And importantly, mitochondrial dysfunction is now being considered as one of the hallmarks of aging. And because of that, researchers have become increasingly interested in interventions that target mitochondrial function directly. And that's where today's three compounds come in. So let's start with MitoQ MitoQ was developed at the University of Otago here in New Zealand by professors Mike Murphy and Robin Smith. It's a mitochondria-targeted antioxidant derived from CoQ10, and antioxidants aren't new, but the difference here is the location.
Traditional antioxidants circulate throughout the body, but MitoQ was specifically engineered to accumulate inside the mitochondria. This targeting matters because mitochondria are one of the primary sources of reactive oxygen species or ROS.
A certain amount of ROS is completely normal, and in fact, ROS are important signaling molecules, but when ROS production becomes excessive, oxidative stress can damage mitochondrial proteins, lipids, and DNA. Over time, we know that that damage can contribute to mitochondrial dysfunction. So MITOQ was designed to accumulate right where that oxidative stress originates.
That's why most of the human research on MitoQ has focused on conditions where mitochondrial oxidative stress appears to be elevated, particularly vascular aging, endothelial dysfunction, hypertension, peripheral artery disease, exercise-related oxidative damage, and healthy aging more broadly.
One of the landmark studies showed that six weeks of MitoQ supplementation improved endothelial function in healthy older adults,
And researchers have also observed reductions in oxidized LDL and markers associated with oxidative stress. And lastly, what's particularly interesting is that MitoQ is one of the few mitochondrial interventions with a substantial human clinical evidence base.
Now let's move on to Urolithin A. So urolithin A comes from a completely different place. It's a metabolite produced by gut microbes when they break down compounds called elagitanins, which are found in foods like pomegranate and walnuts.
What makes urolithin A interesting is its connection to mitophagy. And mitophagy is sometimes described as that mitochondrial housekeeping. So it's the process that cells use to identify damaged or dysfunctional mitochondria and recycle them. This is incredibly important because damaged mitochondria need to be removed so that healthier mitochondria can take their place.
As we age, mitophagy appears to become less efficient and dysfunctional mitochondria can begin accumulating. And Urolithin A has been studied primarily because it activates signaling pathways associated with mitochondrial quality control and mitochondrial renewal.
So while MitoQ is focused largely on reducing oxidative damage occurring in mitochondria, Urolithin A focuses on helping the cell identify and remove mitochondria that are no longer functioning properly. It's less involved in protection and more involved in recycling and renewal. And human research has largely focused on muscle health, physical performance and mitochondrial biomarkers in older adults.
Several studies have reported improvements in muscle endurance and markers associated with mitochondrial function.
Now what about mitophagy and MitoQ ? MitoQ and Urolithin A are often compared with people assuming that MitoQ is the antioxidant and Urolithin A supports mitophagy, but one thing that emerges from the broader MitoQ research library is that mitochondrial oxidative stress and mitophagy are tightly connected.
And several preclinical studies using MitoQ have actually shown effects on mitophagy pathways. Researchers have reported influences on pathways like the PINK1 Parkin pathway and also mitochondrial quality control processes in models involving cardiovascular disease, diabetes, kidney disease, and environmental stresses.
So MitoQ wasn't designed as a mitophagy activator, but by improving the mitochondrial environment, it may indirectly influence processes involved in mitochondrial quality control.
Now let's talk about methylene blue because this one is different again. So methylene blue is not primarily an antioxidant and it's not a mitophagy compound. So instead, its most discussed mitochondrial mechanism involves the electron transport chain. Within mitochondria, energy production depends on the movement of electrons through the electron transport chain. If that electron flow becomes disrupted or inefficient,
Methylene blue can act as an alternative electron carrier. So in simple terms, it can help electrons move through parts of the respiratory chain when certain components aren't functioning optimally. So if MitoQ is helping manage excessive mitochondrial oxidative stress and urolithin A is helping to clear damage mitochondria, methylene blue is focused on helping electrons continue moving through the energy production system.
It's also worth noting that methylene blue has a much more complex clinical and safety profile. So it exists as a pharmaceutical drug and it also carries important medication interactions. It also displays a hormetic dose response, meaning more is not necessarily better. And unlike MITOQ,
Much of its clinical use historically has not centered on mitochondrial health. its established medical uses include specific hospital applications. So when it comes to which one is best, We've now established that each compound is targeting a different mitochondrial challenge. MitoQ is primarily concerned with reducing excess mitochondrial oxidative stress. Urolithin A works to improve mitochondrial quality control and renewal, and methylene blue addresses electron transport chain bottlenecks. Because they're not addressing the same problems, they're not necessarily competing solutions. One theme emerging from mitochondrial research is that mitochondrial dysfunction is rarely caused by a single issue.
It's often oxidative stress impaired quality control plus altered mitochondrial dynamics plus disrupted signaling plus changes in energy production all occurring together Which is why mitochondrial biology is so fascinating and so complex. So if you take away one thing from today's episode, let it be that MitoQ Urolithin A, and methylene blue don't target the same aspect of mitochondrial biology. So understanding those differences is far more useful than trying to decide which one is universally the best.
Thank you so much for listening to this episode of the Mitopod. If you'd like to explore the research behind today's discussion, we'll link the studies and further reading in the show notes, As always, this episode is intended for educational purposes only and should not be considered medical advice. We'll see you next time on the Mitopod.
